Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Myocardial Revascularization Surgery Hits a Plateau

Hopes were raised high by the ARTS study, when set to show the benefit of bilateral internal mammary arteries (BIMA) during coronary artery bypass graft surgery compared over the use of a single internal mammary artery (SIMA) at 10 year follow up, but only one sub-study was able to show an advantage over radial grafts.

La meseta por la que transcurre la cirugía desde hace varios añosSimilarly, hopes were raised high by the long-term benefits of off-pump versus on-pump coronary artery bypass grafting (CABG), with a list of potential benefits that got longer and longer by the minute that has only led to disappointment. Nothing has changed in the CABG scene for years, and though it is still an excellent revascularization strategy for many patients, it has reached a plateau and there are no further studies to broaden our horizon.

 

And even though cutting-edge stents come out day after day, these also appear to be reaching a plateau. All new devices, despite their many theoretical advantages, have at best been shown non-inferior when compared against the gold standard (the everolimus eluting stent), let alone compared against bioresorbable scaffolds.


Read also: Practical Management of Coronary Perforations.


The present study compared long term survival and morbidity after on pump and off pump CABG.

 

Mandatory clinical and administrative registries were linked to identify patients who underwent CABG between 2005 and 2011, by surgeons who had performed at least 100 off-pump or on-pump CABG operations (to meet expert operator criterion). Survival, stroke, myocardial infarction, repeat revascularization, and new dialysis requirement were analyzed using propensity score and other methods. Median follow-up was 6.8 years.

 

During this period, out of 42570 patients undergoing CABG, 6950 off pump and 15295 on pump patients met inclusion criteria.


Read also: How to predict post TAVR quality of life in “real world” patients.


Off pump CABG was associated to higher mortality (33.4% vs. 29.6% at 10 years; HR: 1.11; CI 95%: 1.04 to 1.18; p=0.002) compared against on pump. In addition, off pump CABG was associated to more chances of incomplete revascularization (15.7% vs. 8.8%; p<0.001), which resulted a mortality predictor at long term (HR: 1.10; CI 95% CI: 1.03 to 1.17; p=0.006) and new revascularization rate also resulted higher (15.4% vs. 14.0% at 10 years; HR: 1.17; CI 95%: 1.01 to 1.37; p=0.048).

 

There were no differences in stroke, acute myocardial infarction or new dialysis.

 

Conclusion

Off pump CABG was associated to higher incomplete revascularization, higher new revascularization rate and higher mortality at 10 years, compared against on pump CABG. These data suggest on pump CABG might be the appropriate choice for most patients undergoing myocardial revascularization surgery.

 

Original title: Long-Term Outcomes After Off-Pump Versus On-Pump Coronary Artery Bypass Grafting by Experienced Surgeons.

Reference: Joanna Chikwe et al. J Am Coll Cardiol 2018;72:1478–86.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...